The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N-(3-cyanophenyl)-7-(pyridin-4-yl)-2,3-dihydrobenzo[f][1,4]oxazepine-4(5H)-carboxamide ID: ALA4763234
PubChem CID: 162660699
Max Phase: Preclinical
Molecular Formula: C22H18N4O2
Molecular Weight: 370.41
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: N#Cc1cccc(NC(=O)N2CCOc3ccc(-c4ccncc4)cc3C2)c1
Standard InChI: InChI=1S/C22H18N4O2/c23-14-16-2-1-3-20(12-16)25-22(27)26-10-11-28-21-5-4-18(13-19(21)15-26)17-6-8-24-9-7-17/h1-9,12-13H,10-11,15H2,(H,25,27)
Standard InChI Key: ZMKWHQJUHAUIFS-UHFFFAOYSA-N
Molfile:
RDKit 2D
28 31 0 0 0 0 0 0 0 0999 V2000
29.2771 -15.7495 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.2760 -16.5690 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.9840 -16.9780 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.9823 -15.3406 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.5699 -16.9773 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.8622 -16.5665 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.1546 -16.9738 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.1536 -17.7919 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
27.8659 -18.2009 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.5706 -17.7912 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.6957 -16.5661 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.6909 -15.7459 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.3319 -15.2249 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
31.3457 -17.0757 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.1363 -15.3976 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.1487 -16.8845 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
32.4977 -16.1369 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.6650 -17.5179 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.3746 -18.2818 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
33.4717 -17.3875 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
33.9880 -18.0209 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.6949 -18.7833 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.2105 -19.4164 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.0181 -19.2862 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.3076 -18.5175 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.7901 -17.8877 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.1129 -18.3826 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.9192 -18.2494 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 11 2 0
12 4 2 0
4 1 1 0
5 6 2 0
6 7 1 0
7 8 2 0
8 9 1 0
9 10 2 0
10 5 1 0
2 5 1 0
11 12 1 0
12 13 1 0
11 14 1 0
13 15 1 0
14 16 1 0
15 17 1 0
16 17 1 0
16 18 1 0
18 19 2 0
18 20 1 0
20 21 1 0
21 22 2 0
22 23 1 0
23 24 2 0
24 25 1 0
25 26 2 0
26 21 1 0
27 28 3 0
25 27 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 370.41Molecular Weight (Monoisotopic): 370.1430AlogP: 4.05#Rotatable Bonds: 2Polar Surface Area: 78.25Molecular Species: NEUTRALHBA: 4HBD: 1#RO5 Violations: ┄HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: 13.02CX Basic pKa: 5.16CX LogP: 3.01CX LogD: 3.00Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.74Np Likeness Score: -1.91
References 1. Wilson JE,Kurukulasuriya R,Sinz C,Lombardo M,Bender K,Parker D,Sherer EC,Costa M,Dingley K,Li X,Mitelman S,Tong S,Bugianesi R,Ehrhardt A,Priest B,Ratliff K,Ujjainwalla F,Nargund R,Hagmann WK,Edmondson S. (2016) Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes., 26 (12.0): [PMID:27240550 ] [10.1016/j.bmcl.2016.04.018 ]